Author/Authors :
Yoon، نويسنده , , Young-Kwang and Im، نويسنده , , Seock-Ah and Min، نويسنده , , Ahrum and Kim، نويسنده , , Hwang-Phill and Hur، نويسنده , , Hyung-Seok and Lee، نويسنده , , Kyung-Hun and Han، نويسنده , , Sae-Won and Song، نويسنده , , Sang-Hyun and Youn Oh، نويسنده , , Do and Kim، نويسنده , , Tae-You and Ho Kim، نويسنده , , Woo and Bang، نويسنده , , Yung-Jue and Kim، نويسنده ,
Abstract :
We evaluated the effects of sunitinib monotherapy and in combination with cisplatin in human gastric cancer cell lines. Sunitinib showed antiproliferative effect in gastric cancer cells line with high PDGFRA expression. Knockdown of PDGFRA showed that sunitinib sensitivity was correlated with the basal expression of PDGFRA. Synergistic growth inhibitory activity in combination with cisplatin was identified. We further explored how sunitinib potentiated the activity of cisplatin. We found that sunitinib treatment resulted in the down-regulation of ERCC1 expression via the modulation of PDGFRA expression in gastric cancer cells. The effect was verified via SNU484 xenograft model. Our data support the rationale of clinical trial using sunitinib in combination of cisplatin in gastric cancer.
